CD274 and neoplasm: A recently developed MNK1/2 inhibitor, Tomivosertib or eFT-508 [16], has been shown to inhibit the expression of PD-L1 and slow down tumor progression in the mouse model of liver cancer [17], but the efficacy in TNBC is still unknown.